
|Articles|March 1, 2004
Etanercept shows safety, efficacy through five years
Washington -- A new study presented in poster form at the recent AAD meeting concludes that etanercept continues to post an excellent record for the treatment of rheumatoid arthritis. The drug maintains its safety profile and clinical efficacy for treatment durations of more than five years.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Accepts Addition of Bemotrizinol as First New Sunscreen Ingredient in 20 Years
2
Moving Past Dermal Filler Trends to Focus on Healthy Skin Aging
3
Once-Daily Zasocitinib Rivals Injectable Biologics for Skin Clearance, Phase 3 Data Show
4
Filling the HS Treatment Gap: Ruxolitinib Targets Early-Stage Disease
5














